NCT07219680Recruiting
Intervention for Communication Quality of Life in Primary Progressive Aphasia
Intervention to Promote Communication Quality of Life for Persons With Language-Led Dementia and Their Partners: A Randomized Pilot Trial
Source: ClinicalTrials.gov · Last updated 21 Apr 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn whether a personalized, multi-component, virtual speech language treatment program can improve communication and quality of life for adults with primary progressive aphasia (PPA) and their primary communication partners. The study will enroll participants who speak English and/or Spanish. The main questions the study aims to answer are: * Is the telerehabilitation program feasible and acceptable for people with PPA and their study partners? * Do participants with PPA and study partners find treatment beneficial? * What patterns of treatment response are seen in participants? * Which outcome measures are most useful for evaluating changes in communication and quality of life? Researchers will compare participants who receive intervention immediately to participants assigned to a waitlist control group (who will receive treatment after a delay) to see whether participation in the treatment program is associated with improvements in communication and quality of life. Participants will: * Take part in speech language therapy sessions delivered by video visit that combine restorative, compensatory, and partner-focused communication strategies. Treatment may take place after a waiting period. * Receive education and communication training together with their partner. * Complete speech, language, and cognitive assessments. * Complete questionnaires about communication abilities, daily functioning, and quality of life.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 20 Oct 2025
- Start date
- 1 Apr 2026
- Primary completion date
- 31 Aug 2027
- Lead sponsor
- Maya Henry
- Diseases
- Frontotemporal dementia
- NCT number
- NCT07219680
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 1 Apr 2026 to the primary completion date, 31 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Psychiatric diagnosis that can account for symptoms
Other
- Other central nervous system or medical diagnosis that can account for symptoms
Who the study is looking for
- A PPA (Gorno-Tempini et al., 2011) or "PPA-plus" (Mesulam et al., 2001) diagnosis
- MMSE score of 15 or higher and must be able to produce single monosyllabic words intelligibly
- Must speak English, Spanish or both languages (i.e., bilingual speakers of English or Spanish)
- Hearing and vision adequate for participation in teleconference meetings
- Must have a study partner available (someone who will commit to attending teleconference sessions, as needed, during assessment and treatment phases)
- Partners must express willingness to attend and participate in assessment and treatment sessions, including those targeting dyadic communication goals
- Partners must speak English, Spanish or both languages (i.e., bilingual speakers of English or Spanish)
- Partner's hearing and vision should be adequate for participation in teleconference meetings
- The participant and/or study partner must have basic experience using a computer.
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Texas Coordinator of this site? Confirm its status | Austin | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.